Trial Profile

The safety and efficacy of 7MW3711 in advanced malignant solid tumor .

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 27 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 7MW 3711 (Primary)
Indications Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

27 Feb 2024 New trial record
20 Feb 2024 According to Mabwell Biosciences media release, the company received IND Approval from the U.S. Food and Drug Administration (FDA) for the drug 7MW3711 for advanced malignant solid tumor .

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com